<![CDATA[Curcumin analog compounds are α,β unsaturated compounds through simplifying the beta diketo group to monoketo, which has better bioavailability and a more stable structure than curcumin compounds. This study aims to determine the α-amylase inhibitory activity on symmetric curcumin analog compounds, namely the compounds 2,6-bis(3,4-dimethoxybenzylidine)cyclohexanone (A) and 2,6-bis(3,4-dimethoxybenzylidine)cyclopentanone (B). as well as testing its synergistic interaction with ferulic acid in vitro. The α-amylase inhibition test was carried out using an iodine reagent and a starch solution as a substrate. The absorbance value was measured using a UV-vis spectrophotometer (λ 568 nm), and the % inhibition was calculated. The average value of the optimum α-amylase inhibition percentage for compounds A, B, and ferulic acid, respectively is 58.17%; 22.95%, and 93.52%. Based on the synergistic interaction, it was concluded that compounds A and B showed synergistic activity with ferulic acid. The percentage of α-amylase inhibition in the concentration ratio of curcumin analog A: ferulic acid (1:8) was 98.65%, and curcumin analog B: ferulic acid (1:4) was 98.37%. This shows that combining compounds between symmetrical curcumin analogs and ferulic acid can increase the activity of antidiabetic drug candidate compounds compared to single compounds. This study offers a new approach by testing the potential combination of curcumin and ferulic acid analogues as α-amylase inhibitors in vitro, demonstrating a synergy that has not been widely explored and opening up opportunities for developing more effective natural antidiabetic therapies.]]>
Copyrights © 2025
